EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
HCC Summit 201914-16 February 2019 Lisbon
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| P07-01 | efficacy and safety of transarterial radioembolization with yttrium-90 in patients with hepatocellular carcinoma in the context of real clinical practice | Christie Perelló |  Received |
 |
|||
| P01-01 | The dual role of RIP3-dependent signalling in controlling steatosis and carcinogenesis in experimental non-alcoholic steatohepatitis | Marta B. Afonso | Received |
|
|||
| P06-01 | Lymphocytes count predicts the evolution of patients with hepatocellular carcinoma treated with sorafenib | Leonardo Gomes Da Fonseca | Received |
|
|||
| P02-01 | The role of Albumin-Bilirubin grade (ALBI) and Neutrophil-lymphocyte ratio(NLR) in predicting survival in patients with Hepatocellular carcinoma(HCC) | Vinay kumar Balachandrakumar | Received |
|
|||
| LBP-01 | CDK12 inhibition mediates DNA damage and suppresses adaptive responses to sorafenib treatment in hepatocellular carcinoma | Cun Wang | Received |
|
|||
| P05-01 | Expression of galectin 3 and the clinical presentation of Hepatocellular Carcinoma recurrence after liver transplantation | Norma Filgueira | Received |
|
|||
| P03-01 | Efficacy of sorafenib and lenvatinib for hepatitis etiology: a network meta-analysis of phase III trial | Andrea Casadei Gardini | Received |
|
|||
| P06-02 | HCC recurrence after DAA treatment in HCV patients. | Maria Guarino | Received |
|
|||
| P03-02 | Thermal ablation is a safe and effective treatment for intrahepatic cholangiocarcinoma in patients with cirrhosis | Alvaro Diaz-Gonzalez | Received |
|
|||
| P05-02 | Serum levels of protein induced vitamin K absence or antagonist-II (PIVKA-II) and alpha-fetoprotein (AFP) at baseline predict overall survival in patients with hepatocellular carcinoma (HCC) | Silvia Gaia | Received |
|
|||
| P01-02 | Liver NK cells from NLG4 KO mice inhibited progressions of hepatocellular carcinoma of C57BL/6 mice model through decrease in p53 and AKT expressions | Johnny Amer | Received |
|
|||
| P07-02 | Thyroid hormone inhibits hepatocellular carcinoma development by reverting the metabolic reprogramming of cancer cells | ANDREA PERRA | Received |
|
|||
| LBP-02 | Attenuated XPO5-mediated export of pre-miRNA confers sorafenib resistance in HCC | Zhongjie Lin | Received |
|
|||
| P04-02 | Hepatic epithelioid hemangioendothelioma: an international multicenter study | Marco Sanduzzi Zamparelli | Received |
|
|||
| P07-03 | Lack of CCL2 limits the development of HCC in a model of obesity-associated carcinogenesis | Benedetta Piombanti | Received |
|
|||
| P01-03 | pivotal role of xist in regulating immune checkpoint pd-1/pd-l1 through a shared pathway between mir-194-5p and mir-155-5p in hepatocellular carcinoma | Sara Atwa | Received |
|
|||
| P03-03 | A novel versatile murine cholangiocarcinoma model via CRISPR/Cas9-mediated sequential oncogenic mutations of liver organoids | Michael Dill | Received |
|
|||
| P05-03 | Molecular evaluation of skin proliferative lesions in patients with hepatocellular carcinoma under sorafenib treatment | Leonardo Gomes da Fonseca | Received |
|
|||
| P04-03 | Validation of modified ALBI-T score as a prognostic model to evaluate Egyptian patients with hepatocellular carcinoma | Omar Elshaarawy | Received |
|
|||
| P06-03 | Direct-acting antiviral treatment and recurrence of hepatocellular carcinoma: a single center experience | Marco Guarracino | Received |
|
|||
| LBP-03 | The long non-coding RNA SNHG16 affects prognosis in hepatocellular carcinoma by regulating p62 expression | Jian-Hong Zhong | Received |
|
|||
| P07-04 | circulating mir-4507 as a novel prognostic biomarker in hepatocellular carcinoma | Muhammad Yogi Pratama | Received |
|
|||
| P01-04 | endocan versus alphafetoprotein as a novel biomarker in hepatitis C related cirrhosis with hepatocellular carcinoma | Abdel Ghani Badran | Received |
|
|||
| P02-04 | clinical characteristics of liver cirrhosis and hepatocellular carcinoma occurring after fontan operation | Eun Ju Cho | Received |
|
|||
| P04-04 | Oncological long term benefit in case of anatomic versus parenchyma-sparing resection for hepatocarcinoma: does the extension matter? A meta-analysis of high quality propensity matched and randomized studies. | Simone Famularo | Received |
|
|||
| LBP-04 | Influence of sustained virological response in diagnostic performance of alpha-fetoprotein for hepatocellular carcinoma in patients with HCV-cirrhosis | Ana Gómez-Outomuro | Received |
|
|||
| P03-04 | Liver polyploidization during NAFLD: a Gatekeeper against Replication Stress | Romain Donne | Received |
|
|||
| P05-04 | Safety and effectiveness of regorafenib in recurrent HCC after liver transplantation and progression on sorafenib: a real-life multicentre study | Massimo Iavarone | Received |
|
|||
| P06-04 | The pattern of de novo hepatocellular carcinoma evolution in patients with hepatitis C virus following direct acting antiviral therapy needs to be clarified. | Cassia Regina Guedes Leal | Received |
|
|||
| P02-05 | Patients with hepatocellular carcinoma (HCC) treated with sorafenib who develop adverse effects during the first 60 days present a characteristic immunologic profile | Josep Corominas Argente del Castillo | Received |
|
|||
| P01-05 | The effect of socio-economic deprivation and distance to travel in the survival of patients with Hepatocellular carcinoma in Liverpool region(UK) | Vinay kumar Balachandrakumar | Received |
|
|||
| LBP-05 | Influence of treatment with direct-acting antivirals in hepatocellular carcinoma development in patients with Hepatitis C Virus-related cirrhosis | Ana Gómez-Outomuro | Received |
|
|||
| P05-05 | Experience in the use of sorafenib impacts on reasons leading to discontinuation and chance of long term response | Luca Ielasi | Received |
|
|||
| P03-05 | Radioembolization with Yttrium-90 microspheres for intermediate-advanced hepatocellular carcinoma: a single centre real-life experience | Joniada Doraku | Received |
|
|||
| P04-05 | Analysis of the HSD17B13:TA allelic variant as a protective factor towards hepatocellular carcinoma in patients with and without chronic hepatitis C | Martina Fazio | Received |
|
|||
| P06-06 | Somatic mutations and clonal dynamics in healthy and cirrhotic human liver | Matthew Hoare | Received |
|
|||
| P04-06 | Galectin 3 as a risk factor for recurrence of Hepatocellular Carcinoma after liver transplantation | Norma Filgueira | Received |
|
|||
| P05-06 | The current status of ing treatment modalities for naiive hepatocellular carcinoma patients over 70 years old : Single-center experience | Kyung Sik Kim | Received |
|
|||
| P02-06 | Dissecting the landscape of (epi-)genetic alterations during sequential evolution of liver cancer. | Carolin Czauderna | Received |
|
|||
| P07-06 | yttrium -90 trans arterial radioembolisation (tare) is an effective treatment for the downstaging of patients with hepatocellular carcinoma: a monocentric experience in a tertiary center | Helene Regnault | Received |
|
|||
| P01-06 | Anticlonogenic and apoptotic effect of metformin on cholangiocarcinoma cell line | Gulden Baskol | Received |
|
|||
| P03-06 | Globally relevant models for hepatocellular carcinoma survival applicable before and after TACE | Omar Elshaarawy | Received |
|
|||
| LBP-06 | Identification of novel epigenetic targets in the fibrotic stroma associated with HCC. | Marina Barcena-Varela | Received |
|
|||
| P05-07 | fas and p53-upregulated modulator of apoptosis in hepatocellular carcinoma cellular death | Rusdina Bte Ladju | Received |
|
|||
| P04-07 | Evaluation of LI-RADS v2018 by magnetic resonance in US-detected nodules 2cm in cirrhotics | Alejandro Forner González | Received |
|
|||
| LBP-07 | Glycogen synthase 2 (GYS2) restricts tumor metastatic ability via attenuating autophagy and breaking glycogenic homeostasis in hepatocellular carcinoma | Di Wu | Received |
|
|||
| P06-07 | External beam radiotherapy (EBRT) as an effective and safe treatment in all stages of hepatocellular carcinoma (HCC) with cirrhotic liver disease: a single western institution experience. | Clémence Hollande | Received |
|
|||
| P02-07 | Safety, and tolerability abd efficacy of transarterial chemoemebolization using drug elutind microspheres loaded with antracyclines for the treatment of patients with unresectable hepatocellular carcinome : PARIS study? | Elena Gonzalez | Received |
|
|||
| P03-07 | Non-parenchymal TREM2 halts hepatocarcinogenesis through the inhibition of liver inflammation and hepatocyte proliferation | Ibone Labiano | Received |
|
|||
| P01-07 | Sorafenib-induced pancreatic atrophy and its clinical implication in patients with hepatocellular carcinoma | Francesca Benevento | Received |
|
|||
| P07-07 | What are the predictive factors for long-term survivors with advanced hepatocellular carcinoma treated with sorafenib? | Daniela Reis | Received |
|
|||
| P04-08 | Percutaneous Microwave (MW) ablation is better than Radiofrequency (RFA) to obtain complete response in cirrhotic patients with very early and early hepatocellular carcinoma | Silvia Gaia | Received |
|
|||
| P03-08 | To cure or not to cure intermediate stage hepatocellular carcinoma beyond Milan Criteria: trans-arterial chemoembolization versus surgery in a multicentric matched cohort | Simone Famularo | Received |
|
|||
| P05-08 | Clinical safety, tolerability and adverse events of special interest in a Phase Ib study of atezolizumab (atezo) bevacizumab (bev) in hepatocellular carcinoma (HCC) | Michael Lee | Received |
|
|||
| LBP-08 | The EGF-HER2/ErBb2JNK axis drives intrahepatic cholangiocarcinoma (CCA) development | Francisco Javier Cubero | Received |
|
|||
| P02-08 | Regulation of miRNA expression by Sorafenib in primary human hepatocytes and liver cancer cells | Patricia De La Cruz-Ojeda | Received |
|
|||
| P06-08 | AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma | Massimo Iavarone | Received |
|
|||
| P07-08 | Efficacy and safety of the combination of pravastatin and sorafenib as a new therapy for the treatment of advanced hepatocellular carcinoma | Ioana Riaño | Received |
|
|||
| P07-09 | miR-21/PPARalpha activation in NASH promotes progression towards hepatocellular carcinoma | Pedro Miguel Rodrigues | Received |
|
|||
| P05-09 | cRel is a novel tumour suppressor in Hepatocellular Carcinoma | Jack Leslie | Received |
|
|||
| P04-09 | A multicentric study on real-life impact of nivolumab in patients with hepatocellular carcinoma | Leonardo Gomes Da Fonseca | Received |
|
|||
| P01-09 | Treatment of BCLC-B hepatocellular carcinoma with transarterial chemoembolization with novel polyethylene glicol doxorubicin drug-eluting microspheres: a pharmacokinetic study | Elena Gonzalez | Received |
|
|||
| P02-09 | NASH as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role: case-control study | Stefania De Lorenzo | Received |
|
|||
| P06-09 | Capecitabine in advanced hepatocellular carcinoma: a multicenter experience | Filippo Pelizzaro | Received |
|
|||
| P03-09 | comparison between rates of hepatitis c-related hepatocellular carcinoma recurrence in patients who received or not direct acting antiviral treatment | Hend Shousha | Received |
|
|||
| P01-10 | beta-catenin signaling controls NKG2D ligands expression in liver tumorigenesis | Mathilde Cadoux | Received |
|
|||
| P05-10 | The development of hepatocellular carcinoma is not predicted by genetic variants in caucasian compensated HBV cirrhotics treated by Entecavir of Tenofovir for 10 years | Alessandro Loglio | Received |
|
|||
| P07-10 | Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma | Stephanie Roessler | Received |
|
|||
| P02-10 | Dual CCR2/CCR5 antagonism as macrophage targeted therapy in experimental hepatocellular carcinoma | Helena Degroote | Received |
|
|||
| P04-10 | Sulfatase-2 (SULF2) in the hepatocellular carcinoma microenvironment orchestrates disease progression and therapy resistance | Misti McCain | Received |
|
|||
| P03-10 | Interventional targeting of Cyclin E1 during hepatocarcinogenesis limits stem cell traits and hepatic myeloid cell homing and attenuates cancer progression | Roland Sonntag | Received |
|
|||
| P06-10 | recurrence of hepatocellular carcinoma in patients with complete response treated with direct acting antivirals in clinical practice | Christie Perelló | Received |
|
|||
| P06-11 | line1 retrotransposons - key drivers of hepatocellular carcinoma via TGF beta signalling | Bassier Zadran | Received |
|
|||
| P04-11 | Analysis of epithelial to mesenchymal transition markers expression in liver of mice fed high fat diet | Katarzyna Mi&281;kus | Received |
|
|||
| P03-11 | AXL positive myeloid cells are expanded within tumours and in the peripheral circulation in patients with hepatocellular carcinoma | Sujit Mukherjee | Received |
|
|||
| P05-11 | Impact of screening in the average survival time of cirrhotic patients with HCC | Ana Rita Lopes | Received |
|
|||
| P02-11 | Polyploidy Spectrum: A new marker of HCC tumor classification | Chantal Desdouets | Received |
|
|||
| P07-11 | Obeticholic acid decreased alpha-Feto-protein levels in HCC through Farnesoid X receptor (FXR) | Ahmed Salhab | Received |
|
|||
| P01-11 | ESM-1 as a marker of macrotrabecular-massive hepatocellular carcinoma | Julien Calderaro | Received |
|
|||
| P05-12 | Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis | Rocio Macias | Received |
|
|||
| P02-12 | protein kinase erk5 modulates liver regeneration process in mice | Giovanni Di Maira | Received |
|
|||
| P04-12 | CXCL5 induced by the synergy of transforming growth factor-beta and Axl signaling causes neutrophil extracellular trap formation in hepatocellular carcinoma | Wolfgang Mikulits | Received |
|
|||
| P06-12 | survival and prognostic factors of patients with advanced hepatocellular carcinoma and treated with sorafinib | Hend Shousha | Received |
|
|||
| P03-12 | Hepatocellular carcinoma systemic therapy: predictive factors of sorafenib benefit | Sofia Tavares | Received |
|
|||
| P07-12 | Incidence of hepatocellular carcinoma after hepatitis C cure with DAA in a cohort of patients with advanced liver disease. Results from a prospective screening program. | Marco Sanduzzi Zamparelli | Received |
|
|||
| P01-12 | Analysis and characterization of mitochondrial DNA mutations in The Cancer Genome Atlas hepatocellular carcinoma cohort | Coada Camelia | Received |
|
|||
| P01-13 | Time varying mHAP III is the most accurate score in predicting survival in patients with hepatocellular carcinoma (HCC) undergoing transarterial chemo-embolization (TACE) | Claudia Campani | Received |
|
|||
| P06-13 | Predictive factors of tumor recurrence and overall survival in patients with hepatocellular carcinoma firstly treated by locoregional therapies: results of a retrospective cohort study. | Ramy Younes | Received |
|
|||
| P03-13 | CEUS pattern of hepatocellular carcinoma: prognostic implication | Eleonora Terzi | Received |
|
|||
| P05-13 | Imaging and Clinical Features of HCC nidus: A Retrospective Study | Leonardo Pisani | Received |
|
|||
| P07-13 | Sorafenib for patients with recurrent hepatocellular carcinoma after liver transplantation: intrinsic resistance or not? | Vito Sansone | Received |
|
|||
| P04-13 | The hepatocyte specific role of the NRF2/KEAP1 axis for HCC progression during chronic liver disease | Antje Mohs | Received |
|
|||
| P04-14 | Clinical validation of the role of contrast-enhanced ultrasound in the EASL guidelines for the diagnosis of hepatocellular carcinoma | LORENZO MULAZZANI | Received |
|
|||
| P06-14 | post-transplant de novo neoplasms: role of HCC in risk stratification | SHALABY SARAH | Received |
|
|||
| P01-14 | Oncostatin M induces increased invasiveness and angiogenesis in hepatic cancer cells through HIF1-alpha-related release of VEGF-A | Stefania Cannito | Received |
|
|||
| P07-14 | Sequential systemic treatment in advanced hepatocellular carcinoma prolongs median overall survival to more than three years. | Kornelius Schulze | Received |
|
|||
| P03-14 | Efficacy and safety of thermal ablation in patients with hepatocellular carcinoma (HCC) and high comorbidity (hc) | Maria Torner | Received |
|
|||
| P05-15 | Circulating neutrophils present a dysfunctional immunophenotype in patients with hepatocellular carcinoma | João Maurício | Received |
|
|||
| P03-15 | Early experience with lenvatinib for the treatment of advanced hepatocellular carcinoma in real world practice in Japan | Kaoru Tsuchiya | Received |
|
|||
| P07-15 | Dual role of C3G in hepatocarcinoma tumor growth and progression. Implication in the HGF/c-Met signaling pathway | Celia Sequera Hurtado | Received |
|
|||
| P04-15 | Changes in the circulating miRNome profiles after therapy identify miRNA predictive biomarkers for HCC recurrence | Devis Pascut | Received |
|
|||
| P01-15 | Milticentric prospective study of validation of angiogenesis polymorphisms in hepatocellular patients treated with sorafenib. Interim analysis of INNOVATE study | Andrea Casadei Gardini | Received |
|
|||
| P02-15 | hepatocellular carcinoma identification models for patients with hcv-related chronic liver disease using data mining techniques | Hend Shousha | Received |
|
|||
| P02-16 | Energymetabolism and cell motility/adhesion defect in circulating NK-cells frompatients with Hepatocellular Carcinoma | Alessandra Zecca | Received |
|
|||
| P01-16 | Cancer stem cell sub-population drives resistance to anti-angiogenic therapies in hepatocellular carcinoma | Darko Castven | Received |
|
|||
| P04-16 | Acquisition of stem cell-like features in human cholangiocarcinoma is associated with an oxidative metabolism | Mirella Pastore | Received |
|
|||
| P03-16 | Combination of ubiquitin carboxy-terminal hydrolase L1 inhibition and Sorafenib treatment in experimental hepatocellular carcinoma dampens tumor aggressiveness and reduces in vitro functional liver cancer stem cell characteristics | Astrid Vandierendonck | Received |
|
|||
| P05-17 | impact of interval between complete ablation of hepatocellular carcinoma and start of direct acting antivirals to manage chronic hepatitis C infection | Hend Shousha | Received |
|
|||
| P01-17 | genetic variation in death receptor domain 4 (DR4) gene and the susceptibility to hepatitis-c related hepatocellular carcinoma | Hend Shousha | Received |
|
|||
| P02-17 | mtdh/aeg-1/lyric promotes tumor proliferation and targeted drug resistance in hepatocellular carcinoma | Shunjie Xia | Received |
|
|||
| P03-17 | Color Doppler and contrast-enhanced ultrasonography to manage hemorragic complications occurring after percutaneous thermal ablation of hepatocellular carcinoma. | LETIZIA VERONESE | Received |
|
|||
| P04-17 | Long-term survivors in patients with hepatocellular carcinoma: an ITA.LI.CA. report | Filippo Pelizzaro | Received |
|
|||
HCC Summit 2019
14-16 February 2019 Lisbon
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 14/02/2019 TO 14/02/2020
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
|
|
